Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Dexcom (DXCM) Return on Capital Employed (2016 - 2026)

Dexcom has reported Return on Capital Employed over the past 16 years, most recently at 24.24% for Q1 2026.

  • Quarterly Return on Capital Employed rose 658.0% to 24.24% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 24.24% through Mar 2026, up 658.0% year-over-year, with the annual reading at 21.36% for FY2025, 393.0% up from the prior year.
  • Return on Capital Employed was 24.24% for Q1 2026 at Dexcom, up from 19.09% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 24.24% in Q1 2026 and troughed at 5.48% in Q2 2022.
  • The 5-year median for Return on Capital Employed is 12.97% (2024), against an average of 13.55%.
  • Year-over-year, Return on Capital Employed crashed -349bps in 2022 and then soared 658bps in 2026.
  • A 5-year view of Return on Capital Employed shows it stood at 11.83% in 2022, then increased by 4bps to 12.26% in 2023, then soared by 40bps to 17.21% in 2024, then increased by 11bps to 19.09% in 2025, then rose by 27bps to 24.24% in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Return on Capital Employed are 24.24% (Q1 2026), 19.09% (Q4 2025), and 19.07% (Q3 2025).